US grant sets up MediciNova's MN-166 for Ph II study in meth addiction
This article was originally published in Scrip
Seeking a pharmaceutical approach to methamphetamine addiction, the US National Institute on Drug Abuse (NIDA) has provided a $2.7 million grant that will finance a Phase II study conducted by researchers at the University of California, Los Angeles (UCLA) with MediciNova's MN-166 (ibudilast), an in-licensed compound under development in multiple indications due to its broad anti-neuroinflammatory and neuroprotective actions.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.